AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17870051 — intervention group
Group type: EXPERIMENTAL
Intervention: Winter conditions (without air-conditioning)
Number of subjects: 50
Study 17870051 — intervention group
Group type: COMPARATOR
Intervention: Summer conditions (without air-conditioning)
Number of subjects: 50
Study 17870051 — intervention group
Group type: EXPERIMENTAL
Intervention: Room heating in winter
Number of subjects: 50
Study 17870051 — intervention group
Group type: EXPERIMENTAL
Intervention: Air-conditioning in summer
Number of subjects: 50
Study 16848200 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical antiglaucoma therapy with pilocarpine
Number of subjects: 0
Study 16848200 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical antiglaucoma therapy with latanoprost and pilocarpine
Number of subjects: 0
Study 16848200 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2% and pilocarpine
Number of subjects: 0
Study 16848200 — intervention group
Group type: COMPARATOR
Intervention: Control group (only pilocarpine)
Number of subjects: 0
Study 12482640 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 192
Study 12482640 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192
Study 10682948 — intervention group
Group type: EXPERIMENTAL
Intervention: Vignette of a geriatric, retired patient (n = 100 participants)
Number of subjects: 215
Study 10682948 — intervention group
Group type: COMPARATOR
Intervention: Vignette of a younger, employed patient (n = 115 participants)
Number of subjects: 215
Study 9080750 — intervention group
Group type: EXPERIMENTAL
Intervention: Paired stud retention
Number of subjects: 25
Study 9080750 — intervention group
Group type: EXPERIMENTAL
Intervention: Paired magnetic retention
Number of subjects: 25
Study 9080750 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment success rating
Number of subjects: 25
Study 9080750 — intervention group
Group type: EXPERIMENTAL
Intervention: Healing following Stage I surgery
Number of subjects: 25
Study 9080750 — intervention group
Group type: EXPERIMENTAL
Intervention: Healing following Stage II surgery
Number of subjects: 25
Study 9080750 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-insertion care events
Number of subjects: 25
Study 8401094 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical abortion with mifepristone 600 mg followed by gemeprost 1 mg vaginal pessary
Number of subjects: 363
Study 8401094 — intervention group
Group type: COMPARATOR
Intervention: Vacuum aspiration under general anaesthesia
Number of subjects: 363
Study 8401094 — intervention group
Group type: EXPERIMENTAL
Intervention: Either method (random allocation)
Number of subjects: 363
Study 8401094 — intervention group
Group type: COMPARATOR
Intervention: Vacuum aspiration
Number of subjects: 363
Study 6356325 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 0
Study 6356325 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim and Sulphamethoxazole (TMP-SMX)
Number of subjects: 0
Study 29945799 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrus Microstent (HMS)
Number of subjects: 556
Study 29945799 — intervention group
Group type: COMPARATOR
Intervention: No Microstent (NMS)
Number of subjects: 556
Study 29962422 — intervention group
Group type: COMPARATOR
Intervention: Mechanical Tooth Cleaning (MTC)
Number of subjects: 37
Study 29962422 — intervention group
Group type: EXPERIMENTAL
Intervention: MTC + Ultrasonic Debridement using Universal Insert (UDUI)
Number of subjects: 37
Study 29962422 — intervention group
Group type: EXPERIMENTAL
Intervention: MTC + Ultrasonic Debridement using Probe-shaped Insert (UDPI)
Number of subjects: 37
Study 26562709 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk protein (12 g protein, 7 g essential amino acids)
Number of subjects: 26
Study 26562709 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein (12 g protein, 7 g essential amino acids)
Number of subjects: 26
Study 26562709 — intervention group
Group type: COMPARATOR
Intervention: Rice milk (nonprotein control, 12 g protein, 7 g essential amino acids)
Number of subjects: 26
Study 24709513 — intervention group
Group type: EXPERIMENTAL
Intervention: CBCT
Number of subjects: 40
Study 24709513 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiography
Number of subjects: 40
Study 21309653 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic drop (Lactobacillus reuteri)
Number of subjects: 19
Study 21309653 — intervention group
Group type: COMPARATOR
Intervention: Placebo drop
Number of subjects: 19
Study 19560838 — intervention group
Group type: EXPERIMENTAL
Intervention: 1+1 hydromorphone patient‐driven protocol (1 mg IV hydromorphone followed by a second 1‐mg dose 15 minutes later if requested)
Number of subjects: 94
Study 19560838 — intervention group
Group type: COMPARATOR
Intervention: Traditional physician‐driven administration of opioids (any IV opioid at the discretion of the attending physician)
Number of subjects: 94
Study 19560838 — intervention group
Group type: EXPERIMENTAL
Intervention: 1+1 hydromorphone patient‐driven protocol
Number of subjects: 94
Study 19560838 — intervention group
Group type: EXPERIMENTAL
Intervention: 1+1 hydromorphone patient‐driven protocol and Traditional physician‐driven administration
Number of subjects: 94
Study 17955433 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccine
Number of subjects: 12343
Study 17955433 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12343
Study 16763407 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxen sodium
Number of subjects: 120
Study 16763407 — intervention group
Group type: EXPERIMENTAL
Intervention: meloxicam
Number of subjects: 120
Study 16763407 — intervention group
Group type: EXPERIMENTAL
Intervention: rofecoxib
Number of subjects: 120
Study 16763407 — intervention group
Group type: EXPERIMENTAL
Intervention: paracetamol
Number of subjects: 120
Study 16763407 — intervention group
Group type: EXPERIMENTAL
Intervention: dipyrone
Number of subjects: 120
Study 16763407 — intervention group
Group type: EXPERIMENTAL
Intervention: etodolac
Number of subjects: 120
Study 15375100 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete intervention arm (systematic strategy with feedback, education, and quality improvement sessions)
Number of subjects: 194
Study 15375100 — intervention group
Group type: COMPARATOR
Intervention: Feedback arm (feedback only)
Number of subjects: 194
Study 15375100 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete intervention arm (systematic strategy)
Number of subjects: 194
Study 15321106 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm saline (37 degrees C)
Number of subjects: 113
Study 15321106 — intervention group
Group type: COMPARATOR
Intervention: Cold saline (21 degrees C)
Number of subjects: 113
Study 8794833 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 38
Study 8794833 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 38
Study 1825515 — intervention group
Group type: EXPERIMENTAL
Intervention: dichloromethylene diphosphonate (CL2MDP)
Number of subjects: 38
Study 1825515 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 38
Study 6373344 — intervention group
Group type: EXPERIMENTAL
Intervention: Almitrine bismesylate (50 mg b.d. for the first three months, with possible increase of 50 mg after the third and/or sixth month if PaO2 increase is less than 5 mmHg and well tolerated)
Number of subjects: 100
Study 6373344 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 30286303 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified milk (200 mL daily, enriched with 3 μg of vitamin D3)
Number of subjects: 239
Study 30286303 — intervention group
Group type: COMPARATOR
Intervention: Nonfortified milk (200 mL daily, natural abundance of vitamin D3, about 1.5 μg)
Number of subjects: 239
Study 28783201 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 months DAPT in low DAPT score group
Number of subjects: 3976
Study 28783201 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 months DAPT in low DAPT score group
Number of subjects: 3976
Study 28783201 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 months DAPT in high DAPT score group
Number of subjects: 3976
Study 28783201 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 months DAPT in high DAPT score group
Number of subjects: 3976
Study 25106026 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular plus resistance training (CRT)
Number of subjects: 64
Study 25106026 — intervention group
Group type: EXPERIMENTAL
Intervention: High‐intensity strength training (HIST)
Number of subjects: 64
Study 25106026 — intervention group
Group type: COMPARATOR
Intervention: No exercise (Control)
Number of subjects: 64
Study 23999280 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-glycemic index dietary intervention for 12 weeks
Number of subjects: 21
Study 21114545 — intervention group
Group type: EXPERIMENTAL
Intervention: HDUP
Number of subjects: 41
Study 21114545 — intervention group
Group type: COMPARATOR
Intervention: MDUP
Number of subjects: 41
Study 21114545 — intervention group
Group type: EXPERIMENTAL
Intervention: DUP increase
Number of subjects: 41
Study 17960410 — intervention group
Group type: EXPERIMENTAL
Intervention: Debridement 6 and 12 days postoperatively
Number of subjects: 121
Study 17960410 — intervention group
Group type: COMPARATOR
Intervention: Saline irrigation
Number of subjects: 121
Study 17960410 — intervention group
Group type: COMPARATOR
Intervention: Packing in middle meatus for 5 days
Number of subjects: 121
Study 16755554 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole (0.125 to 0.75 mg/day)
Number of subjects: 150
Study 16755554 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 12580994 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin therapy
Number of subjects: 11
Study 12580994 — intervention group
Group type: COMPARATOR
Intervention: Control group (active, normolipidaemic)
Number of subjects: 11
Study 10952698 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased iodine intake (272 microg/l) in preterm formula
Number of subjects: 121
Study 10952698 — intervention group
Group type: COMPARATOR
Intervention: Standard iodine intake (68 microg/l) in preterm formula
Number of subjects: 121
Study 8776813 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month depot formulation
Number of subjects: 159
Study 8776813 — intervention group
Group type: COMPARATOR
Intervention: 1-month depot formulation
Number of subjects: 159
Study 8529150 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium miniplates with IMF only during surgery, released thereafter; one titanium mini-plate for angle fractures, two for fractures anterior to the mental foramen.
Number of subjects: 74
Study 8529150 — intervention group
Group type: COMPARATOR
Intervention: Open reduction and intermaxillary fixation (IMF) for 5 weeks; stainless steel wire for angle fractures, stainless steel plate for fractures anterior to the mental foramen.
Number of subjects: 74
Study 6511996 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (dose mg/kg/day)
Number of subjects: 21
Study 6511996 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol serum concentrations (15 to 40 ng/ml)
Number of subjects: 21
Study 30768684 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral briefing followed by a 4-min planning discussion
Number of subjects: 44
Study 30768684 — intervention group
Group type: COMPARATOR
Intervention: Control group (no planning discussion)
Number of subjects: 44
Study 28277391 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous supportive care
Number of subjects: 72
Study 28277391 — intervention group
Group type: COMPARATOR
Intervention: Routine hospital care
Number of subjects: 72
Study 27864246 — intervention group
Group type: EXPERIMENTAL
Intervention: What Were We Thinking (WWWT) psychoeducational intervention
Number of subjects: 359
Study 27864246 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 359
Study 24559812 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupuncture with electrical stimulation (verum group, n=28)
Number of subjects: 56
Study 24559812 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment with a P-Stim® dummy (placebo group, n=28)
Number of subjects: 56
Study 22647517 — intervention group
Group type: EXPERIMENTAL
Intervention: Phlebotomy (n = 33)
Number of subjects: 64
Study 22647517 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 31)
Number of subjects: 64
Study 20621734 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib (EGFR tyrosine kinase inhibitor)
Number of subjects: 23
Study 16996172 — intervention group
Group type: EXPERIMENTAL
Intervention: Peru-15 vaccine (2x10^8 cfu)
Number of subjects: 240
Study 16996172 — intervention group
Group type: COMPARATOR
Intervention: Peru-15 vaccine (2x10^7 cfu)
Number of subjects: 240
Study 16358380 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dosage levothyroxine (L-T4) at an initial dosage of 3.21-5.81 microg/(kg.d), average of 16.25±3.87 microg/d, for a mean duration of therapy of 28.09±9.56 months.
Number of subjects: 57
Study 16358380 — intervention group
Group type: COMPARATOR
Intervention: Control group of 29 healthy peers.
Number of subjects: 57
Study 16358380 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up evaluations including TT3, TT4, TSH serum levels, thyroid gland morphology, bone age, growth development, and DQ.
Number of subjects: 57
Study 11528582 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (200 mg/week)
Number of subjects: 0
Study 11528582 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9780524 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct hypnotic suggestions (Harvard Group Scale of Hypnotizability)
Number of subjects: 0
Study 9780524 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect hypnotic suggestions (Alman Wexler Indirect Hypnotic Susceptibility Scale)
Number of subjects: 0
Study 8169385 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoids
Number of subjects: 44
Study 8169385 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 3215160 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight gain prevention treatment (monthly newsletters, financial incentives, optional education course)
Number of subjects: 219
Study 3215160 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 219
Study 31172827 — intervention group
Group type: EXPERIMENTAL
Intervention: NO3‐‐rich beetroot juice (BJ)
Number of subjects: 15
Study 31172827 — intervention group
Group type: COMPARATOR
Intervention: NO3‐‐depleted (placebo) beetroot juice
Number of subjects: 15
Study 28719151 — intervention group
Group type: EXPERIMENTAL
Intervention: Support and Problem Solving (SPS) for 1.5 months
Number of subjects: 500
Study 28719151 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Case Management for 4.5 months
Number of subjects: 500
Study 28719151 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Case Management + Antidepressant Medication for 6 months
Number of subjects: 500
Study 28719151 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioural Case Management + Placebo for 6 months
Number of subjects: 500
Study 28623969 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm delivery and term delivery after suspected preterm labour
Number of subjects: 132
Study 28623969 — intervention group
Group type: EXPERIMENTAL
Intervention: Placental samples from preterm and term deliveries after suspected preterm labour
Number of subjects: 132
Study 28623969 — intervention group
Group type: EXPERIMENTAL
Intervention: Suspected preterm labour
Number of subjects: 132
Study 28623969 — intervention group
Group type: COMPARATOR
Intervention: Term delivery without suspected preterm labour
Number of subjects: 132
Study 26200520 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep intervention program (details not specified)
Number of subjects: 50
Study 26200520 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective sleep measures (total sleep time, total numbers of awakenings, total wake time)
Number of subjects: 50
Study 26200520 — intervention group
Group type: EXPERIMENTAL
Intervention: Participant characteristics (marital status, use of sleep medication, comorbidity, posttraumatic stress disorder, living arrangement)
Number of subjects: 50
Study 23998400 — intervention group
Group type: EXPERIMENTAL
Intervention: Segmentectomy
Number of subjects: 210
Study 23998400 — intervention group
Group type: COMPARATOR
Intervention: Wedge resection
Number of subjects: 210
Study 20938664 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant 250 mg/month
Number of subjects: 234
Study 20938664 — intervention group
Group type: COMPARATOR
Intervention: Anastrozole 1 mg/day
Number of subjects: 234
Study 18394217 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency (two) meal ingestion (LOFREQ(MEAL))
Number of subjects: 5
Study 18394217 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency (twelve) meal ingestion (HIFREQ(MEAL))
Number of subjects: 5
Study 18394217 — intervention group
Group type: COMPARATOR
Intervention: Fasting (FAST)
Number of subjects: 5
Study 16798391 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (6.3/50 mg/kg)
Number of subjects: 652
Study 16798391 — intervention group
Group type: COMPARATOR
Intervention: Artesunate-mefloquine (12/25 mg/kg)
Number of subjects: 652
Study 16798391 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine
Number of subjects: 652
Study 16798391 — intervention group
Group type: COMPARATOR
Intervention: Artesunate-mefloquine
Number of subjects: 652
Study 12824948 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (80 mg per day)
Number of subjects: 60
Study 12824948 — intervention group
Group type: COMPARATOR
Intervention: Control (no aspirin)
Number of subjects: 60
Study 12824948 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrent abortions (IgGacl positive)
Number of subjects: 60
Study 11070146 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (1.5 g)
Number of subjects: 60
Study 11070146 — intervention group
Group type: EXPERIMENTAL
Intervention: Corn oil (4.5 g)
Number of subjects: 60
Study 11070146 — intervention group
Group type: COMPARATOR
Intervention: Sesame oil (4.5 g)
Number of subjects: 60
Study 11070146 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 9007920 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 42
Study 9007920 — intervention group
Group type: COMPARATOR
Intervention: 3% mepivacaine
Number of subjects: 42
Study 8284243 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase plus heparin
Number of subjects: 91
Study 8284243 — intervention group
Group type: COMPARATOR
Intervention: Heparin therapy alone
Number of subjects: 91
Study 3693584 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasted state
Number of subjects: 12
Study 3693584 — intervention group
Group type: EXPERIMENTAL
Intervention: Fed state
Number of subjects: 12
Study 3693584 — intervention group
Group type: COMPARATOR
Intervention: Control (Fasted state)
Number of subjects: 12
Study 30741894 — intervention group
Group type: COMPARATOR
Intervention: Combination treatment (steroids and diuretics simultaneously for 2 weeks)
Number of subjects: 92
Study 30741894 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential treatment (diuretics for 2 weeks followed by steroids for another 2 weeks if no response)
Number of subjects: 92
Study 28137247 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary support group
Number of subjects: 67
Study 28137247 — intervention group
Group type: COMPARATOR
Intervention: Social support control group
Number of subjects: 67
Study 26510135 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based multi-component lifestyle intervention program (classroom curriculum, school environment support, family involvement, fun programs/events) for 1 year
Number of subjects: 1182
Study 26510135 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based multi-component lifestyle intervention program
Number of subjects: 1182
Study 23433403 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg/d
Number of subjects: 22
Study 23433403 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 10 mg/d
Number of subjects: 22
Study 21875858 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine
Number of subjects: 411
Study 21875858 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 411
Study 19724191 — intervention group
Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir (DRV/r)
Number of subjects: 80
Study 17372320 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity Program (80 minutes of PA offered 5 days/week for 10 months)
Number of subjects: 136
Study 15007086 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed Tomography (CT)
Number of subjects: 530
Study 15007086 — intervention group
Group type: EXPERIMENTAL
Intervention: Carcino-embryonic antigen (CEA)
Number of subjects: 530
Study 15007086 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic detection
Number of subjects: 530
Study 15007086 — intervention group
Group type: EXPERIMENTAL
Intervention: CT and CEA combined
Number of subjects: 530
Study 12469051 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin and warfarin therapy
Number of subjects: 244
Study 12469051 — intervention group
Group type: COMPARATOR
Intervention: Aspirin therapy
Number of subjects: 244
Study 9846593 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine ingestion (5 mg/kg fat-free mass)
Number of subjects: 20
Study 8137114 — intervention group
Group type: EXPERIMENTAL
Intervention: mianserin (antidepressant)
Number of subjects: 50
Study 2512256 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate ibuprofen (2400 mg/day)
Number of subjects: 122
Study 2512256 — intervention group
Group type: COMPARATOR
Intervention: Placebo medication for 48 h, followed by ibuprofen (2400 mg/day) from the 3rd day onwards
Number of subjects: 122
Study 1150903 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin administered concurrently with warfarin for five days
Number of subjects: 0
Study 1150903 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral dose of warfarin administered before and after ten consecutive days of oral indomethacin administration
Number of subjects: 0
Study 480048 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen 2.5 mg/kg
Number of subjects: 0
Study 480048 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen 7.5 mg/kg
Number of subjects: 0